Drug intelligence / Profile preview

2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules

Overview

This compound belongs to the class of organic compounds known as phenylpyrazoles. It is a small molecule with a molecular formula of C25H20N4O and a molecular weight of 392.5 g/mol. The drug is not approved for any conditions and does not have any known clinical trials. Its mechanism of action is not explicitly stated in the available data.

Other names: 2-((4-(4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline2-(4-(4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl)phenoxymethyl)quinoline2-{4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxymethyl}quinoline

Beyond the preview

Go deeper on 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline.

Explore the full profile